The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

It isn't difficult for a modestly priced stock to leap in value on a positive news item. That's the dynamic behind the monster rise these past few days of clinical-stage biotech CytomX Therapeutics ...

Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

CytomX Therapeutics, Inc.‘s (NASDAQ:CTMX) share price was up 94.46% at last check on Monday. The stock surged after the company reported interim Phase 1 data for its EpCAM PROBODY ADC candidate, ...

CytomX provide an initial CX-904 Phase 1a dose escalation update on May 8 after the close of markets. CytomX and Amgen are developing CX-904, a T-cell-engaging bispecific Probody candidate against the ...

Dr. Sean McCarthy framed 2026 as “a transformational year for CytomX,” citing “excellent clinical progress with Varseta-M in late line colorectal cancer” and positioning Varseta-M as “the only ...

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and Regeneron's Veloci-Bi® platforms - - Regeneron secures ...

The MarketWatch News Department was not involved in the creation of this content. - Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY(R) ADC ...

Shares of CytomX Therapeutics CTMX were up 30.8% this past month after it announced strategic business updates and outlined key pipeline goals for 2026. The encouraging clinical progress with its ...